# A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma

> **NCT03914443** · PHASE1 · COMPLETED · sponsor: **National Cancer Center, Japan** · enrollment: 37 (actual)

## Conditions studied

- Locally Advanced Esophageal Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Nivolumab
- **DRUG:** 5-FU
- **DRUG:** CDDP
- **DRUG:** DTX

## Key facts

- **NCT ID:** NCT03914443
- **Lead sponsor:** National Cancer Center, Japan
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-07
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-05-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03914443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03914443, "A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03914443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*